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Background: Multiple-drug-resistant Gram-negative bacteria (MDR-GNB)-associated
neonatal ventriculitis is a life-threatening complication that needs timely diagnosis
and effective treatment with broad-spectrum antimicrobials in critical-care settings.
Inadequate penetration of antibiotics through the blood–brain barrier also demands
an intraventricular (IVT) route of administration. This study reports mortality and
neurodevelopmental sequelae of neonates till 18 months of age, who received IVT-colistin
for treating MDR-GNB associated ventriculitis.
Methods: In a case series of seven neonates with ventriculitis due to MDR-GNB at NICU
of Aga Khan University Hospital, Pakistan, between June 2015 and 2018, we reviewed
IVT-colistin therapy in critically ill neonates. Treatment outcomes were assessed based
on clinical sign’s resolution and MDR-GNB eradication in subsequent CSF cultures.
Neurodevelopmental outcomes were evaluated at 18 months after discharge.
Results: The average birth weight was 1.38 kg (range: 1.02–1.5 kg), and the average
gestational age was 30.7 weeks (ranged: 26–34 weeks). All neonates reported colistinsensitive MDR-GNB in CSF, five with Acinetobacter baumannii, and polymicrobial CNS
infection was found in two patients (one due to Klebsiella pneumonia and A. baumannii
and one due to K. pneumonia and Escherichia coli). All neonates received IVT colistin
and concomitant intravenous meropenem, and five of them also received intravenous
colistin. One neonate died. At the 18-month assessment, only one neonate had cerebral
palsy and hydrocephaly and 50% had seizure disorders.
Conclusion: Practicing intraventricular antibiotics in the neonatal population is
challenging but may be used successfully, especially to overcome the limitation of poor
penetration through the blood–brain barrier.
Keywords: colistin, intraventricular antibiotics, neonates, multiple drugs resistant, ventriculitis
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BACKGROUND

had MDR-GNB-associated ventriculitis and treated with IVT
colistin. Here, we are sharing the onset of CNS infection,
treatment, and outcome of neonates in terms of survival and
neurological complications.

Central nervous system (CNS) infections are caused by several
organisms, clinically presented as meningitis, ventriculitis, and
brain abscess. The type of organisms involved and their
susceptibility to available antimicrobials are the important factors
in the clinical outcome and survival of these patients. It is
crucial to timely recognize and manage these patients to reduce
morbidity and mortality rates.
Nosocomial CNS infections are mostly a significant
complication in patients undergoing neurosurgery (1), ranging
from 0.3 to 6.5% in these patients (2–4). Its occurrence is
about 8% in patients with external ventricular drain (EVD)
(5, 6). In addition, one-third of the ventriculoperitoneal (VP)
shunts implanted may lead to CNS infection (7). Neonatal CNS
infections may occur concomitantly with the onset of Gramnegative pathogen-associated bacteremia (8–10). The overall
neonatal mortality due to infections have reduced over the last
few decades, but neonatal CNS infection-related morbidity
remains almost unchanged (11, 12). Recent research has been
focusing on improved diagnostic and preventive techniques and
adjunctive therapies for improved neonatal outcomes (13).
The type of causative organisms of neonatal CNS infections
depends on the gestational/postnatal age and facility setting
(11, 14, 15). The treatment target for the nosocomial infections
mostly involves multiple-drug-resistant (MDR) Gram-negative
bacteria (GNB) such as Acinetobacter baumannii and Klebsiella
pneumoniae (16). Studies have reported higher mortality ranges
from 71.3 to 72.6% in patients with MDR-GNB-associated
ventriculitis after neurosurgical procedures, mostly because of
microbial resistance and inadequate antimicrobial penetration
through the blood–brain barrier (BBB) (17, 18). Similarly, Chen
et al. have reported up to 30% mortality rates in patients with
carbapenem-resistant organism-associated CNS infections (19).
Fortunately, A. baumannii and K. pneumoniae are found
susceptible to colistin, but limited penetration of colistin to
cerebrospinal fluid (CSF) remains another challenge. These
subtherapeutic levels require very high intravenous (IV) colistin
doses. Consequently, the intrathecal (IT) or intraventricular
(IVT) route is more appropriate to achieve the obligatory
therapeutic colistin concentration to combat the MDR-GNB
(20–24).
In adults and pediatric patients, neurological complications
and sequelae of CNS infection have been studied. More
severe illness, specific pathogens, earlier onset of paresis, and
seizure have been reported as associated risk factors (25–27).
Ventriculitis secondary to meningitis may occur in >20% of
neonates (28). Survivors of neonatal meningitis and ventriculitis
are at a much higher risk for neurodevelopmental impairments
including motor function, hearing, vision, hydrocephalus, and
seizure disorder.
Until today, very limited data is there about the usage
of IVT/IT colistin in neonates, mostly in the form of case
reports (29–31). That is not enough for the development of an
exact guideline for IT/IVT colistin use in neonates for MDRGNB-associated CNS infection. We encountered seven neonates
in our neonatal intensive care unit (NICU) in 3 years, who
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METHOD
Study Design and Data Collection
In this retrospective case series, we reviewed the medical record
of seven neonates at our 24-bedded NICU and the step-down
unit of the Aga Khan University Hospital, Karachi, Pakistan,
between June 2015 and June 2018. All the neonates included for
the study were reported with the isolation of MDR-GNB from the
CSF, developed ventriculitis during the NICU stay, and received
colistin via the IVT route for >72 h.
Due to the high mortality rate with the emergence of MDRGNB infections and the concern about poor CNS penetration
of IV colistin, we offered adjunctive IVT colistin treatment to
these neonates who had CNS infection. Infection control and
preventive measures were strictly followed by the healthcare
providers, such as contact isolation and hand hygiene.
For each case, data were collected regarding the demographic
characteristics (gestational and postnatal age, sex, birth weight);
primary and current diagnosis; the clinical and laboratory
information about the infections; onset of CNS infection;
hematological parameters (hemoglobin, neutrophil count,
platelet counts, white blood cell (WBC) count, and C-reactive
protein); presence of medical devices; concomitant antibiotic
use along with susceptibility pattern, dose, and duration of IV;
IVT colistin therapy; days to sterilized CSF; and IVT colistinassociated adverse effects and the outcome. After discharge,
all surviving patients underwent a neurological examination
performed by a pediatric neurologist, and the record was
reviewed for the neurodevelopmental assessment reports, based
on the broad classification of status at 18 months of age. It
comprised of documentations of abnormal neurodevelopmental
outcomes like motor dysfunction (cerebral palsy or monoplegia)
and visual and hearing deficit with standardized criterion.

Treatment Regimen of Intraventricular
Colistin
Colistimethate sodium (CMS) is available in a vial containing
80 mg dry powder equivalent to 33.3 mg colistin base and further
diluted in 2 ml of sterile preservative-free normal saline (NS).
Colistin (base) was administered at a dose of 0.16–0.24 mg/kg
as a single daily dose via the intraventricular route (21, 32, 33).
All IVT doses were dispensed to nursing units in prefilled readyto-administer form. The dose was administered through EVD
by the neurosurgery team. Neonates were monitored for any
hemodynamic changes during and after each dose (34).

Operational Definition
Nosocomial infections were defined according to the standard
definition by the Centers for Disease Control and Prevention
(35). The IVT colistin-associated most common and lifethreatening adverse effect is reversible chemical ventriculitis,
which presents with sterile CSF cultures and signs of meningeal
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irritation, that is, altered mental state, fever, increased WBC, and
lower glucose concentration in the CSF, and the presentation
is like bacterial meningitis (21). MDRO was defined as an
isolated pathogen non-susceptible to at least one agent of ≥3
antimicrobial categories (36). MDR-GNB-associated meningitis
was defined as the presence of MDR-GNB in CSF cultures,
and clinical presentation of neonatal meningitis is defined as
the presence of signs like hyper or hypothermia, respiratory
distress, hypotonia, lethargy or irritability, feed intolerance,
apnea, lower heart rate and blood pressures, bulging anterior
fontanel, seizures, and hypo or hyperglycemia (37). Choroid
plexitis and inflammation of the ependymal lining of ventricles
is called ventriculitis. Clinical symptoms of meningitis, failure to
respond to appropriate antibiotic therapy, and signs of elevated
intracranial pressure (ICP) suggest the diagnosis of ventriculitis.
Further magnetic resonance imaging (MRI), lumbar puncture
(LP), and fontanel tape aid in the diagnosis of ventriculitis
(38, 39).

average birth weight was 1.38 kg (range: 1.02 to 1.5 kg), and
the average gestational age was 30.7 weeks (range: 26 to 34
weeks). At the time of onset of ventriculitis, the average age of
neonates was 26.9 days (range: 18 to 44 days). Five neonates
had intraventricular hemorrhage (IVH), and one neonate had
hypoxic–ischemic encephalopathy as associated diagnosis with
ventriculitis. Two neonates had a history of pneumonia, and two
had persistent pulmonary hypertension of the newborn (PPHN)
before the onset of CNS infection. Four neonates had a VP shunt
while three patients had no drainage system.
Based on the previous culture reports, susceptibility pattern,
and clinical grounds, to treat the ongoing infections neonates
were given other IV antibiotics. Three neonates were treated
with cefotaxime and amikacin initially, then switched to
meropenem, either alone or in combination with colistin or
vancomycin. Three neonates were treated with meropenem plus
vancomycin. One neonate received ceftazidime and amikacin
after discontinuation of meropenem. Four neonates developed
concomitant pneumonia (three with A. baumannii and one
with K. pneumoniae). The blood cultures of five neonates were
also positive with MDR-GNB (four with A. baumannii and one
with K. pneumoniae).
From all the cases, five neonates were treated with
concomitant IV colistin in the dose of 5 mg/kg/day in daily
divided doses for an average duration of 15.6 days (range: 14
to 21 days), whereas all of seven neonates received concomitant
meropenem and three of them were given amikacin. The average
duration between the diagnosis of CSF infection and IVT colistin
therapy was 5.6 days (range: 3 to 12 days), and the average period
to attain sterile CSF among six survived neonates was 3.72 days
(range: 2 to 8 days). Among all, one neonate died during the
treatment, due to A. baumannii. Till the last examination, CSF
was unsterile in this patient and had received three doses of IVT
colistin on alternate days.
All six survived neonates who achieved the sterile CSF phase
were cured without relapse after completion of the treatment
course. On average, neonates received IVT colistin for 7.4 days
(range: 7 to 10 days). Intraventricular colistin-associated adverse
effect was developed in one neonate and thus received IVT
colistin on alternate days.
Table 2 shows the results of the neurodevelopment assessment
of survived infants at 18 months of age. One of the neonates who
followed in the neurology clinic had cerebral palsy (CP), seizure
disorder (on anticonvulsant therapy), and impaired hearing and
vision. One neonate had hydrocephalus, epilepsy, and developed
retinopathy of prematurity (ROP). Both cases were on follow-up
with a neurologist. From the remaining four, one baby received
ROP treatment and one was on antiepileptic; otherwise, these
four babies were found normal at the 18-month assessment.

Microbiology
For assessing the treatment response, the CSF of each neonate
was collected and sent for chemical and microscopic analysis
prior to IVT colistin administration. GNB were identified and
checked for antibiotic susceptibility through the Vitek-2 compact
system. Furthermore, colistin susceptibility of isolated GNB was
confirmed by using the broth microdilution method. These
isolated pathogens with minimum inhibitory concentration
(MIC) of ≤2 mg/dl were documented as colistin-sensitive using
Clinical Laboratory Standards Institute (CLSI) guidelines (40).

Outcome Measures and Data Analysis
There were two primary outcomes of this study: (i) the cure of the
patient fulfilling the following criteria: (a) MDR-GNB eradication
in subsequent CSF cultures and (b) resolution of clinical signs
of neonatal meningitis and with no further requirement of
antimicrobial therapy; and (ii) neurodevelopmental outcomes
till 18 months follow up after discharge. In the tables,
we incorporated the demographic, clinical, treatment, and
neurodevelopmental outcome details of each case.

RESULTS
During the study period, 3,264 neonates were admitted to
our NICU. A total of 153 neonates received colistin therapy
through any route. Of 153 neonates, 15 patients had cultureproven meningitis. Seven neonates developed ventriculitis and
reported the isolation of colistin-sensitive MDR-GNB in CSF
culture, thus treated with IVT colistin. Five of which were due
to A. baumannii, and polymicrobial CNS infection was found
in two patients (one of which was due to K. pneumonia and
A. baumannii and one of which was due to K. pneumonia and
Escherichia coli). All these critically ill neonates with MDR-GNB
infections had received empirical antimicrobial therapy as per
our institutional guidelines (41).
Neonatal characteristics, isolated MDR-GNB species, and
treatment detail of each case are shown in Table 1. Out of
seven neonates with MDR-GNB infections, five were male, the
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DISCUSSION
Ventriculitis secondary to meningitis is more common in
neonates (42) and may occur in >20% of neonates with
meningitis (28). Moreover, significantly higher morbidity
and mortality due to MDR-GNB-associated meningitis and
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Variables

Cases
1

2

3

4

5

6

7

GA (weeks)

28

30

33

26

32

34

32

Gender

Female

Male

Male

Female

Male

Male

Male

BW (kg)

1.21

1.45

1.65

1.02

1.5

1.5

1.32

APGAR (at 1 & 5min)

7/8

9/9

1/2

1/3

6/9

3/5

5/9

MOD

Cesarean

Cesarean

Cesarean

delivered vaginally

delivered vaginally

delivered vaginally

Cesarean

Underlying illness

MAS, PPHN, IVH

RDS,IVH

HIE

RDS, VAP, IVH

Sepsis, IVH

sepsis, IVH and

TTN, PPHN

Age at the time of onset of CSF infection (days)

34

18

21

44

22

25

24

foreign body

VPS

VPS

VPS

-

Clinical manifestations of CSF infection onset

Hydrocephalus,
Apnea

Hydrocephalus, fever Hydrocephaly, fever,
seizures and apnea

vomiting and feed
intolerance, full
fontanel,
hydrocephalus

Hydrocephalus,
bulging anterior
fontanel, seizures

Hussain et al.
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TABLE 1 | Neonatal clinical characteristics and treatment outcome.

VPS
irritable, hydrocephalus, Hydrocephalus,
bulging anterior
vomiting, fever
fontanel, feed
intolerance, seizures

Laboratory investigations at onset of CSF infection

4

• WBC

• 2200

• 2700

• 1900

• 2500

• 2100

• 2300

• 2600

• Hb

• 11

• 7

• 10

• 9

• 11

• 11

• 10

• Plt

• 140000

• 75000

• 45000

• 70000

• 110000

• 130000

• 100000

• CRP

• 43

• 78

• 53

• 71

• 45

• 62

• 48
KP, AB

E. coli, KP

AB

AB

AB

AB

AB

Colistin, tigecycline
amikacin

Colistin, amikacin

Colistin

Colistin, tigecycline

Colistin and
tigecycline

Colistin, tigecycline, and Colistin, tigecycline
fosfomycin

Antibiotics initially given before known susceptibility

Meropenem
Vancomycin

Meropenem
Vancomycin

Meropenem
Vancomycin

cefotaxime amikacin, cefotaxime amikacin, cefotaxime amikacin,
meropenem, colistin meropenem
meropenem,
vancomycin

Meropenem,
ceftazidime and
amikacin

Time between diagnosis of CSF infection and IVT
colistin therapy (days)

4

3

7

12

4

4

5

Duration of IVT colistin (days)

7

7

5*

8

7

3*

8

Mean IVT colistin doses (mg/kg/day)

0.21

0.2

0.21

0.19

0.23

0.21

0.2

Duration of IV colistin (days)

14

14

15

21

14

-

-

Dose of IV colistin (mg/kg/day)

5

4.8

5

4.8

5

5

5

Duration of concurrent intravenous antibiotic therapy Meropenem-14
amikacin 7

Meropenem-14
amikacin-3

Meropenem-14

Meropenem-14

Meropenem-10

Meropenem-14
amikacin-3

Meropenem-7

Blood culture

-

AB

AB

AB

AB

-

KP

• CSF infection

Cured

Cured

Cured

Cured

Cured

Not Cured till death

Cured

• Patient

Discharged

Discharged

Discharged

Discharged

Discharged

Died

Discharged

Development of IVT colistin related adverse effects

No

No

Yes

No

No

No

No

Days to sterilize CSF

3

2

8

4

5

Not achieved

4

Outcomes

GA, gestational age; BW, birth weight; MOD, mode of delivery; CSF, cerebrospinal fluid; CRP, C-reactive protein (mg/L); IVT, intraventricular; IV, intravenous; WBC, white blood cells count (cells/mm3 ); Hb, hemoglobin (g/dl); Plt, platelets
count (cells/mm3 ); IVH, intraventricular hemorrhage; PPHN, persistent pulmonary hypertension of the newborn; MAS, meconium aspiration syndrome; RDS, respiratory distress syndrome; HIE, hypoxic ischemic encephalopathy; VAP,
ventilator-associated pneumonia; TTN, transient tachypnea of the newborn; E.coli, Escherichia coli; KP, klebsiella pneumonia; AB, acinetobacter baumannii, VPS, ventriculoperitoneal shunt; * doses given on alternate days.
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TABLE 2 | Neurodevelopment assessment of survived children with ventriculitis at 18 months of age.
Parameters

Case
1

2

3

4

5

Motor dysfunction (cerebral palsy) (yes/No)

No

Hearing defect (Normal/mild/moderate/severe)

Normal

7

No

No

Yes

No

No

Normal

Normal

Moderate

Normal

Normal

Visual deficits (impaired/normal/ROP)

ROP

Normal

Normal

Impaired

ROP

Normal

Hydrocephaly /VP Shunt(Yes/No)

No

No

No

Yes

Yes

No

Seizure Disorder (Yes/No)

No

No

yes

Yes

yes

No

ROP, retinopathy od prematurity.

ventriculitis need extra precautionary measures and further
therapeutic considerations to reduce the consequences of such
life-threatening complications (17–19). Increased pathogen
resistance to most of the antimicrobial agents and their poor
CNS penetration are the contributing factors. Therefore, several
studies have chosen the IVT/IT route of administration to
directly deliver the antibiotic, to achieve the desired therapeutic
steady state to fight against these pathogens (20, 21, 23, 43).
Though meropenem is used empirically for nosocomial
MDR-GNB-associated meningitis and ventriculitis (44, 45),
unfortunately, it is becoming progressively ineffective due to
rapidly increased resistance (more than 40%) among these
pathogens (46). Fortunately, these MDR strains remain sensitive
to polymyxins, an old class of antimicrobial agents from the
1950s (41). However, due to the polycationic structure and the
higher molecular weight polymyxins have a poor capacity to
cross the BBB when administered through the IV route (47).
Consequently, IV colistin (polymyxin E) remains unable to
achieve therapeutic CSF concentration to fight against deadly
MDR-GNB (48).
For treating IVH and posthemorrhagic hydrocephalus in
neonates along with the pharmacological approach, other
modalities, such as EVD, serial lumbar or ventricular taps,
and ventriculoperitoneal (VP) shunts, are used (49–51). In
addition, for administering IVT/IT medications special tools
are needed, such as EVD, but these foreign bodies serve as a
potential infection source (52). In adult studies, the IT route
of administration is used by a repeated lumbar puncture on
daily basis; thus, removal of lumbar drain and EVD is preferred
to prevent foreign bodies’ systemic involvement (20). However,
the IT route of administration is comparatively not feasible and
difficult in neonates; therefore, IVT is preferred (53, 54).
The Infectious Diseases Society of America (IDSA) guidelines
recommend using IV and IT/IVT polymyxins (polymyxin
B and colistin) with meropenem in carbapenem-resistance
strain-associated infections (52). The use of colistin through
IVT/IT routes is advocated in adults’ clinical practices, but
neonatal studies are very limited (21). Karaiskos et al. reviewed
IVT/IT colistin usage in multidrug-resistant gram-negative
strain-associated meningitis and ventriculitis (21), involving 81
patients (71 adult and 10 children/neonates). The clinical and
microbiological outcomes were achieved in 89% of patients.
In addition, nine cases (11%) experienced an adverse effect of
chemical ventriculitis. In our study, only one patient experienced
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this adverse effect. A comparatively shorter duration of IVT
antibiotic use might explain this difference. The CSF cultures of
our patients were persistently sterile, but chances of reinfection
need to be considered. In another review, Katragkou et al.
discussed the treatment of MDR A. baumannii-associated CNS
infection by using IVT/IT colistin alone or as an adjunctive to
systemic antimicrobials (55). In our study, neonatal CSF became
sterile within an average of 3.72 days (range 2–8 days), which is
similar to earlier literature (56, 57). Previous adult and pediatric
studies have concluded that the use of IT/IVT colistin was found
safe and effective (56, 57).
Aminoglycosides, tigecycline, rifampin, and sulbactam have
also been used effectively as alternative therapeutic options (21).
However, in our study meropenem was the only antibiotic used
in all the seven patients concomitant with IVT colistin and IV
colistin was used in 5/7 patients, which could be justified due
to the presence of blood and pulmonary infections. In addition,
combination therapy with colistin, meropenem, and ampicillinsulbactam has been reported to reduce the mortality rate (21).
Colistin resistance among A. baumannii and K. pneumonia
are increasingly reported and a case report from South Africa
identified the presence of colistin-resistant A baumanniiassociated ventriculitis in a neonate (56). Another case report
by Mehar et al. reported septicemia with meningitis due to
carbapenem-resistant (susceptible to colistin) A. baumannii in a
preterm neonate. The infant was successfully treated with IVT
colistin and IV netilmicin (58). MDR-GNB-associated neonatal
ventriculitis and meningitis is a challenge to manage using
conventional IV antibiotics and found inadequate to eradicate
these life-threatening pathogens. Fortunately, all the seven cases
in our study had colistin-susceptible MDR-GNB-associated CNS
infection and the MDR strain did not acquire resistance against
colistin in any patient which resulted in 86% success with IVT
colistin treatment.
A neonatal study for evaluating the neurodevelopmental
defects had reported that from the neonates who experienced
bacterial CNS infection and survived, 67% developed neurologic
sequelae (59). In our study, one neonate died with uncontrolled
seizures, and from survivors, only one neonate who had initial
seizures presented with unfavorable neurological effects at 18
months. From six survived neonates, three developed seizures.
These findings are also supported by a previous study, which
shared that the presence of initial seizure is a significant predictor
of unfavorable outcome (60). To the best of our knowledge, no
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study has been conducted to evaluate the neurodevelopmental
effects at 18 months of age, in preterm neonates, who received
IVT antibiotics for treating MDR-GNB-associated ventriculitis.
The increasing prevalence of MDRO causing neonatal sepsis
including meningitis and ventriculitis in some middle- and
low-income countries is a matter of great concern (41, 56).
Also, the implementation of infection control and prevention
strategies is a global challenge in these regions to control the
spread of MDR-GNB. Furthermore, in our region with limited
advanced NICU settings, the transfer of ill neonates from other
facilities is an additional factor in the spread of MDR pathogens.
Implementation of more firm screening measures may help to
prevent the spread by detecting colonized patients earlier (61).
Fortunately, in our NICU patient cohorting is done to keep the
externally transferred and infected infants in the isolation room
provided negative pressure. Our study had limitations of a singlecentered retrospective case series study design, the association of
confounders, and a small sample size.

implementing and continuing practicing simple infection control
and prevention measures. Further prospective, controlled studies
are warranted.

CONCLUSION

GA, MS, and KH conceptualized the design. GA and JI carried
out data collection. KH and GA contributed to pharmacy
data retrieval. GA wrote the draft. MS, KH, and JI carried
out the analysis. MS supervised the study and critically
revised the subsequent drafts. All authors contributed to the
final manuscript.
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